224
Views
31
CrossRef citations to date
0
Altmetric
Review

Inhalation drug delivery devices and emerging technologies

Pages 1333-1343 | Published online: 02 Mar 2005

Bibliography

  • BISGAARD HS, O'CALLAGHAN C, SMALDONE GC (Eds): Drug Delivery to the Lung. Marcel Dekker, Inc., New York, USA (2002).
  • MOREN F, DOLOVICH MB, NEWHOUSE MT et al. (Eds): Aerosols in Medicine: Principles, Diagnosis and Therapy Elsevier Science Publishing, Amsterdam, The Netherlands (1993).
  • BARNES PJ, DRAZEN JM, RENNARD S et al. (Eds): Asthma and COPD: Basic Mechanisms and Clinical Management. Academic Press, London, UK (2002).
  • CHUNG KF, BARNES PJ: Mediator antagonists. In: Asthma, and COPD: Basic Mechanisms and Clinical Management. Barnes PJ, Drazen JM, Rennard S et al (Eds), Academic Press, London, UK (2002):565–571.
  • SMITH AL: Inhaled antibiotic therapy: what drug? what dose? what regimen? what formulation?' Cystic Fibrosis (2002) 1:S189–S193.
  • CIPOLLA DC, CALRK AR, CHAN H-K et al.: Assessment of aerosol delivery systems for recombinant human deoxyribonuclease. STP Pharma Sciences (1994) 4:50–62.
  • MATHER LE, WOODHOUSE A, WARD ME et al: Pulmonary administration of aerosolized fentanyl: pharmacokinetic analysis of a systemic delivery. Br. J. Clin. Pharmacol (1998) 46:37–43.
  • DERSHWITZ M, WALSH JL, MORISHIGE RJ et al.: Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers. Anesthesiology(2000) 93:619–628.
  • WARD ME, WOODHOUSE A, MATHER LE et al.: Morphine pharmacokinetics after pulmonary administration from a novel aerosol delivery system. Clin. Pharmacol Ther. (1997) 62:596–609.
  • SKYLERJ, CEFALU W, KOURIDES let al: Efficacy of inhaled human insulin in Type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet (2001) 357:331–335.
  • CEFALU W, SKYLER J, KOURIDES I et al.: Insulin human insulin treatment in patients with Type 2 diabetes mellitus. Ann. Intern. Med. (2001) 134:203–207.
  • PERERA A, KAPITZA C, NOSEK L et al.: Absorption and metabolic effect of inhaled insulin. Diabetes Care (2002) 25:2276–2281.
  • CLARK AR: Medical aerosol inhalers: past, present and future. Aerosol Sci. Tech. (1995) 22:374–381.
  • MOHSEN NM: pMDI aerosol momentum manipulation and biotargeted delivery. In: Respiratory Drug Delivery VIII Dalby RN, Byron PR, Peart J, Farr SJ (Eds), Davis Horwood International Publishing, Godalming/Surrey, USA (2002):593–597.
  • VERVAET C, BYRON P: Drug-surfactant-propellant interactions in HFA-formulations. Int. J. Pharm. (1999) 186:13–30.
  • KELLER M: Innovations and perspectives of metered-dose inhalers in pulmonary drug delivery. Int. .1. Pharm. (1999) 186:81–90.
  • MEAKIN BJ, LEWIS DA, GANDERTON D et al.: Countering challenges posed by mimicry of DFD performance using LTA systems. In: Respiratory Drug Delivery VII Dalby RN, Byron PR, Farr SJ, Peart J (Eds), Serentec Press, Raleigh, NC, USA (2000):99–107.
  • STFELY JS, BROWN B, HAMMERBECK DM et al.: Equipping the MDI for the 21st century by expanding its formulation options. In: Respiratory Drug Delivery VIII Dalby RN, Byron PR, Peart J, Farr SJ (Eds), Davis Horwood International Publishing, Godalming/Surrey, USA (2002)207–213.
  • CHAN H-K, GONDA I: Development of systematic theory of suspension inhalation aerosols. II. Aggregates of monodisperse particles nebulised in polydisperse droplets. hat. Pharm. (1988) 41:147–157.
  • NEWHOUSE MT, HIRST PH, DUDDU SP et al: Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest (2003) 124:360–366.
  • ANDERSON SD, BRANNAN JD, CHAN H-K: Use of aerosols for bronchial provocation testing in the laboratory: where we have been and where we are going. Aerosol Med. (2002) 15:313–324.
  • DENYER J, PAVIA D, ZIERENBERG B: New liquid drug aerosol devices for inhalation therapy. Lim Respir. Rev (2000) 10:187–191.
  • KASTELIK JA, WRIGHT GA, AZIZ I et al.: A widely available method for the assessment of aerosol delivery in cystic fibrosis. Pulmon. Pharmacol Ther. (2002) 15:513–519.
  • SOMMERER K, BRAND MP, MULLINGER B et al.: A strategy to optimize peripheral lung deposition in patients with emphysema. In: Respiratory Drug Delivery VIII Dalby RN, Byron PR, Peart J, Farr SJ (Eds), Davis Horwood International Publishing, Godalming/ Surrey, USA (2002):475–478.
  • YOSHIYAMA Y, YAZAKI T, ARAI M et al.: The nebulization of budesonide suspensions by a newly developed mesh nebulizer. In: Respiratory Drug Delivery VIII Dalby RN, Byron PR, Peart J, Farr SJ (Eds), Davis Horwood International Publishing, Godalming/Surrey, USA (2002):487–489.
  • CIPOLLA D, FARR S, FIORE M et al: AREx: synthesis of technologies to provide therapeutic benefits via pulmonary drug delivery. Polymer Preprints (1999) 40:326–327.
  • SIMON M, GOPALAKRISHNAN V: AeroDose'm inhaler - feasibility studies with the aerosol generator. In: Respiratory Drug Delivery VII Dalby RN, Byron PR, Farr SJ, Peart J (Eds), Serentec Press, Raleigh, NC, USA (2000):311–314.
  • WISSINK JM, VAN RIJN CJM: Smart micromachined nozzles for monodisperse aerosol generation using low pressure Rayleigh break-up. In: Respiratory Drug Delivery VIII Dalby RN, Byron PR, Peart J, Farr SJ (Eds), Davis Horwood International Publishing, Godalming/ Surrey, USA (2002):509–512.
  • SMART J, BERG E, BERBRINK 0 et al: TouchSprairm technology: comparison of the droplet size measured with cascade impaction and laser diffraction. In: Respiratory Drug Delivery VIII Dalby RN, Byron PR, Peart J, Farr SJ (Eds), Davis Horwood International Publishing, Godalming/Surrey, USA (2002):525–528.
  • GOODALL S, CHEW N, CHAN K et al.: Aerosolisation of protein solutions using thermal ink jet technology. J. Aerosol Med. (2002)15:351–357.
  • ZIMLICH W, DING J, BUSICK D etal.: Development of multiple clinical and commercial applications using Mystic' inhalation delivery technologies. In: Rey:notary Drug Delivery Viii Dalby RN, Byron PR, PeartJ, Farr SJ (Eds), Davis Horwood International Publishing, Godalming/Surrey, USA (2002):363–366.
  • SPALLEK MW HOCHRAINER D, WACHTEL H: Optimising nozzles for soft mist inhalers. In: Re:yr:rotary Drug Delivery VIII Dalby RN, Byron PR, Peart J, Farr SJ (Eds), Davis Horwood International Publishing, Godalming/Surrey, USA (2002):375–378.
  • VILLAX p, BRITO V, STECKEL H: Development and performance of a new simple dry powder inhaler operating at low airflow rates. In: Respiratory Drug Del/very VIH. Dalby RN, Byron PR, Peart J, Farr SJ (Eds), Davis Horwood International Publishing, Godalming/Surrey, USA (2002):459–462.
  • LIGOTKE NW: Develoment and characterization of a dry powder inhaler. In: Respiratory Drug Delivery V/H. Dalby RN, Byron PR, Peart J, Farr SJ (Eds), Davis Horwood International Publishing, Godalming/Surrey, USA (2002):419–422.
  • CLARK AR, SHIRE SJ: In: Protein Formulation and Delivery McNally EJ (Ed.) Marcel Dekker, Inc., New York, USA (2000):214–216.
  • LUCAS P, CLARKE MJ, ANDERSON M et al.: The role of fine particle excipients in pharmaceutical dry powder aerosols. In: Respiratory Drug Delivery VI Dalby RN, Byron PR, Farr SJ (Eds), Interpharm Press, Ii, USA (1996):243–250.
  • KELLER M, MULLER-WALZ R, GILCHRIST P et al.: Effect of storage on the in vitro performance of formoterol-fumarate powder blends in the SkyePharma MDPI. In: Respiratory Drug Delivery VII Dalby RN, Byron PR, Farr SJ, Peart J (Eds), Serentec Press, Raleigh, NC, USA (2000):511–514.
  • LUCAS P, ANDERSON K, POTTER UJ et al.: Enhancement of small particle size drug powder aerosol formulations using an ultra low density additive. Pharm. Res. (1999) 16:1643–1647.
  • FULTS KA, MILLER IF, HICKEY AJ: Effect of particle morphology on emitted dose of fatty acid-treated disodium cromoglycate powder aerosols. Pharm. Dev Technol (1997) 2:67–79.
  • BYRON PR, PEART J, STANIFORTH JN: Aerosol electrostatics I: properties of fine powders before and after aerosolization by dry powder inhalers. Pharm. Res. (1997) 14:698–705.
  • CHAN H-K, CLARK A, GONDA I et al: Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery. Pharm. Res. (1997) 14:431–437.
  • YAMASHITA C, NISHIBAYASHI T, AKASHI S et al.: A novel formulation of dry powder for inhalation of peptides and proteins. In: Respiratory Drug Delivery VI Dalby RN, Byron PR, Farr SJ (Eds), Interpharm Press, Buffalo Grove, IL, USA (1996): 483–485.
  • CHEW NYK, CHAN H-K: Effect of amino acids on the dispersion of spray dried cromoglycate powders as aerosol. In: Respiratory Drug Delivery VIII Dalby RN, Byron PR, Peart J, Farr SJ (Eds), Davis Horwood International Publishing, Godalming/Surrey, USA (2002):619–622. 1341
  • MAA Y-F, NGUYEN P-A, SWEENEY T et al.: Protein inhalation powders: spray drying versus spray freeze drying. Pharm. Res. (1999) 16:249–254.
  • EDWARDS DA, HANES J, CAPONETTI G et al.: Large porous particles for pulmonary drug delivery. Science (1997) 276:1868–1871.
  • BOT AI, TARARA TE, SMITH DJ et al: Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract. Pharm. Res. (2000) 17:275–283.
  • CHEW NYK, CHAN H-K: Use of solid corrugated particles to enhance powder aerosol performance. Pharm. Res. (2001) 18:1570–1577.
  • DUDDU SP, SISK SA, WALTER YH et al.:Improved lung delivery from a passive dry powder inhaler using an engineered PulmoSphere powder. Pharm. Res. (2002) 19:689–695.
  • OSTRANDER KD, HOVEY DC, KNAPP DA et al.: Potential delivery advantages of spray-dried Nanocrystals' colloidal budesonide with the Clickhaler°. In: Respiratory Drug Delivery VII Dalby RN, Byron PR, Farr SJ, PeartJ (Eds), Serentec Press, Raleigh, NC, USA (2000):447–449.
  • MASTERS K: Spray Drying Handbook (3rd edn). Halsted Press, New York, USA (1979).
  • WATANABE W, AHONEN P, KAUPPINEN E et al.: Novel method for the synthesis of inhalable multicomponent drug powders with controlled morphology and size. In: Respiratory Drug Delivery VIII Dalby RN, Byron PR, Peart J, Farr SJ (Eds), Davis Horwood International Publishing, Godalming/ Surrey, USA (2002):795–797.
  • MAA YF, NGUYEN P-A, SWEENEY T et al.: Protein inhalation powders: spray drying versus spray freeze drying. Pharm. Res. (1999) 16:249–254.
  • CHEN JF, WANG YH, GUO F et al.: Synthesis of nanoparticles with nanotechnology: high-gravity reaction precipitation. Ind. Eng. Chem. Res. (2000) 39:948–954.
  • YORK P, HANNA M: Particle engineering by supercritical fluid technologies for powder inhalation drug delivery. In: Proceedings of Reipiratory Drug Delivery VI Dalby RN, Byron PR, Farr SJ (Eds), Interpharm Press, Buffalo Grove, IL, USA (1996):231–239.
  • SIEVERS RA, SELLERS T, CLARK GS, VILLA JA, MIOSKOWSKI B, CARPENTER J: Supercritical fluid carbon dioxide technologies for fine particle formation for pulmonary drug delivery. 219th ACS National Meeting, San Francisco, CA, USA (March 2000):MSDI–173.
  • BUSTAMI RT, CHAN H-K, DEHGHANI F et al.: Recent application of supercritical fluid technology to pharmaceutical powder systems, Kona, powder and particle (2001) 19:57–70.
  • BUSTAMI RT, CHAN H-K, DEHGHANI F et al: Generation of micro-particles of proteins for aerosol delivery using high pressure modified carbon dioxide. Pharm. Res. (2000) 17:1360–1366.

Websites

  • http://www.nektar.com/content/pipeline Pipeline overview - Nektar Therapeutics.
  • http://www.lungcanceronline.org/ treatment-agents/R/resmycin.html Lung Cancer Online: Treatment agents and regimens: Resmycin (inhaled doxorubicin).
  • http://www.alkermes.com/products/ pipeline.html Product pipeline - Alkermes.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.